Organon & Co. (OGN) Competitors

Organon & Co. (NYSE:OGN) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.

Which has more volatility and risk, OGN or GMAB?

Organon & Co. has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Does the media refer more to OGN or GMAB?

In the previous week, Organon & Co. had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Organon & Co. and 6 mentions for Genmab A/S. Organon & Co.'s average media sentiment score of 1.13 beat Genmab A/S's score of 0.87 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer OGN or GMAB?

Genmab A/S received 144 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 62.65% of users gave Genmab A/S an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.

Company	Underperform	Outperform
Organon & Co.	Outperform Votes 17 33.33%	Underperform Votes 34 66.67%
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%

Do institutionals and insiders believe in OGN or GMAB?

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Is OGN or GMAB more profitable?

Genmab A/S has a net margin of 23.49% compared to Organon & Co.'s net margin of 20.30%. Organon & Co.'s return on equity of 644.70% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	20.30%	644.70%	8.12%
Genmab A/S	23.49%	14.64%	12.37%

Which has stronger earnings & valuation, OGN or GMAB?

Organon & Co. has higher revenue and earnings than Genmab A/S. Organon & Co. is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.26B	0.65	$1.02B	$5.04	3.13
Genmab A/S	$2.39B	5.76	$631.91M	$1.03	20.19

Do analysts recommend OGN or GMAB?

Organon & Co. presently has a consensus target price of $21.33, suggesting a potential upside of 35.32%. Genmab A/S has a consensus target price of $45.20, suggesting a potential upside of 117.31%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Genmab A/S beats Organon & Co. on 11 of the 19 factors compared between the two stocks.